508 related articles for article (PubMed ID: 18778334)
1. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
Saito W; Kase S; Ohgami K; Mori S; Ohno S
Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
[TBL] [Abstract][Full Text] [Related]
6. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
8. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
10. Retinal artery occlusion following intravitreal anti-VEGF therapy.
von Hanno T; Kinge B; Fossen K
Acta Ophthalmol; 2010 Mar; 88(2):263-6. PubMed ID: 19416108
[TBL] [Abstract][Full Text] [Related]
11. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
Retina; 2007; 27(4):426-31. PubMed ID: 17420693
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]